从“方-证要素对应”探讨栀子豉汤及其衍化方的演化规律
|
摘要
栀子豉汤在《伤寒论》中为治疗心中懊恼、烦、热和不得眠等症的主方,后世对其发展应用治疗诸多病症,且疗效颇佳。"方-证要素对应"是在"方证相应"理论的基础上发展起来,用于探究证候要素与方剂要素之间相互对应的关系,属于临证组方的一种基本思维模式,同时更加强调"理、法、方、药"之间的逻辑关系,从而使配伍组方药物的靶向更加明确。用"方-证要素对应"理论对栀子豉汤及其衍化方进行剖析,探究其演化规律,以扩大栀子豉汤及其衍化方在临床中的应用,拓展用药思路。
Zhizichi Decoction is the main formula for the treatment of annoyance in the heart,vexation,fever and insomnia in the Treatise on Cold-induced and Miscellaneous Diseases. Later generations expand and apply it to treat diverse diseases and its curative effect is quite good."Formula-pattern element correspondence"is developed on the basis of the theory of"correspondence between formula and pattern"and is used to explore the relationship between the pattern elements and the formula elements. It is a basic mode of thinking which belongs to formula construction in clinical practice and emphasizes the logical relationship between"theory,method,formula and medicine"at the same time,so that the target of medicinal combination is more clear. In order to expand the application of Zhizichi Decoction and its derived formulas in clinical practice as well as expanding the thinking of medication,the theory of"formula-pattern element correspondence"was used to analyze the Zhizichi Decoction and its derived formulas,and explore its evolutionary rule.
Zhizichi Decoction is the main formula for the treatment of annoyance in the heart,vexation,fever and insomnia in the Treatise on Cold-induced and Miscellaneous Diseases. Later generations expand and apply it to treat diverse diseases and its curative effect is quite good."Formula-pattern element correspondence"is developed on the basis of the theory of"correspondence between formula and pattern"and is used to explore the relationship between the pattern elements and the formula elements. It is a basic mode of thinking which belongs to formula construction in clinical practice and emphasizes the logical relationship between"theory,method,formula and medicine"at the same time,so that the target of medicinal combination is more clear. In order to expand the application of Zhizichi Decoction and its derived formulas in clinical practice as well as expanding the thinking of medication,the theory of"formula-pattern element correspondence"was used to analyze the Zhizichi Decoction and its derived formulas,and explore its evolutionary rule.
引文
[1]王敏,李宇航.基于方-证要素对应的甘麦大枣汤治疗脏躁机制分析[J].北京中医药大学学报,2017,40(5):366-370.
[2]王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1):6-7.
[3]李宇航.谈“证候要素”与“方剂要素”[J].中华中医药杂志,2009,2(24):117-121.
[4]郑丰杰,孙燕,李宇航.经方方证要素解析[J].世界中医药,2015,10(1):1-2.
[5]刘艳红,李宇航.从方证要素对应角度探讨三承气汤及其衍化方演化规律[J].辽宁中医药大学学报,2015,17(4):154-157.
[6]王庆国.伤寒论讲义[M].北京:高等教育出版社,2012:71-75,162,270.
[7]汉·许慎.说文解字[M].北京:九州出版社。2001. 348.
[8]刘完素.素问病机原病式[M].北京:中国医药科技出版社,2011:4,7.
[9]张玉苹,王青青.试论伤寒六经病与“郁”证[J].环球中医药,2014,7(7):557-559.
[10]刘渡舟,傅士垣.伤寒论诠解[M].北京:人民卫生出版社.2013:93.
[11]佚名.黄帝内经[M].北京:线装书局,2012:19.
[12]刘渡舟.新编伤寒论类方[M].北京:人民卫生出版社,2013:90.
[13]范永升.金匮要略[M].北京:中国中医药出版社,2016:185-186.
[14]朱震亨.丹溪心法[M].北京:中国医药科技出版社,2012:185.
[15]薛已.内科摘要[M].南京:江苏科学技术出版社,1985:77.
[16]陈宁宁.《临证指南医案》对栀子豉汤的应用与发挥[J]. 2012,36(5):423-424.
[17]叶天士.临证指南医案[M].北京:人民卫生出版社,2006:20,206-207.
[18]吴鞠通.温病条辨[M].北京:线装书局,2012:217,237.
[19]张鑫蕾,王町囡,孙燕.泻心汤类方及其衍化方演化规律中的“方-证要素对应”思想探究[J].世界中医药,2018,13(3):754-758.
[2]王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1):6-7.
[3]李宇航.谈“证候要素”与“方剂要素”[J].中华中医药杂志,2009,2(24):117-121.
[4]郑丰杰,孙燕,李宇航.经方方证要素解析[J].世界中医药,2015,10(1):1-2.
[5]刘艳红,李宇航.从方证要素对应角度探讨三承气汤及其衍化方演化规律[J].辽宁中医药大学学报,2015,17(4):154-157.
[6]王庆国.伤寒论讲义[M].北京:高等教育出版社,2012:71-75,162,270.
[7]汉·许慎.说文解字[M].北京:九州出版社。2001. 348.
[8]刘完素.素问病机原病式[M].北京:中国医药科技出版社,2011:4,7.
[9]张玉苹,王青青.试论伤寒六经病与“郁”证[J].环球中医药,2014,7(7):557-559.
[10]刘渡舟,傅士垣.伤寒论诠解[M].北京:人民卫生出版社.2013:93.
[11]佚名.黄帝内经[M].北京:线装书局,2012:19.
[12]刘渡舟.新编伤寒论类方[M].北京:人民卫生出版社,2013:90.
[13]范永升.金匮要略[M].北京:中国中医药出版社,2016:185-186.
[14]朱震亨.丹溪心法[M].北京:中国医药科技出版社,2012:185.
[15]薛已.内科摘要[M].南京:江苏科学技术出版社,1985:77.
[16]陈宁宁.《临证指南医案》对栀子豉汤的应用与发挥[J]. 2012,36(5):423-424.
[17]叶天士.临证指南医案[M].北京:人民卫生出版社,2006:20,206-207.
[18]吴鞠通.温病条辨[M].北京:线装书局,2012:217,237.
[19]张鑫蕾,王町囡,孙燕.泻心汤类方及其衍化方演化规律中的“方-证要素对应”思想探究[J].世界中医药,2018,13(3):754-758.